{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:44:55Z","timestamp":1762659895910,"version":"3.37.3"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10067-020-05136-x","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T12:06:45Z","timestamp":1589803605000},"page":"3543-3553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-5856","authenticated-orcid":false,"given":"Dorra","family":"Ben Nessib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanene","family":"Ferjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaouther","family":"Maatallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Rahmouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhia","family":"Kaffel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa","family":"Hamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"key":"5136_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.crohns.2009.11.005","volume":"4","author":"LKPM Brakenhoff","year":"2010","unstructured":"Brakenhoff LKPM, van der Heijde DM, Hommes DW, Huizinga TWJ, Fidder HH (2010) The joint\u2014gut axis in inflammatory bowel diseases. J Crohns Colitis 4:257\u2013268. https:\/\/doi.org\/10.1016\/j.crohns.2009.11.005","journal-title":"J Crohns Colitis"},{"key":"5136_CR2","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.autrev.2014.04.003","volume":"13","author":"I Olivieri","year":"2014","unstructured":"Olivieri I, Cantini F, Castiglione F, Felice C, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Vecchi M, Armuzzi A (2014) Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev 13:822\u2013830. https:\/\/doi.org\/10.1016\/j.autrev.2014.04.003","journal-title":"Autoimmun Rev"},{"key":"5136_CR3","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1080\/17512433.2017.1377609","volume":"10","author":"L Pouillon","year":"2017","unstructured":"Pouillon L, Bossuyt P, Vanderstukken J, Moulin D, Netter P, Danese S, Jouzeau JY, Loeuille D, Peyrin-Biroulet L (2017) Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol 10:1363\u20131374. https:\/\/doi.org\/10.1080\/17512433.2017.1377609","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5136_CR4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/j.1572-0241.2000.02262.x","volume":"95","author":"JB Felder","year":"2000","unstructured":"Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G (2000) Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 95:1949\u20131954. https:\/\/doi.org\/10.1111\/j.1572-0241.2000.02262.x","journal-title":"Am J Gastroenterol"},{"key":"5136_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","volume":"4","author":"WJ Sandborn","year":"2006","unstructured":"Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ (2006) Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 4:203\u2013211. https:\/\/doi.org\/10.1016\/j.cgh.2005.12.002","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5136_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1572-0241.2006.00384.x","volume":"101","author":"Y El Miedany","year":"2006","unstructured":"El Miedany Y, Youssef S, Ahmed I, El Gaafary M (2006) The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 101:311\u2013317. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00384.x","journal-title":"Am J Gastroenterol"},{"doi-asserted-by":"publisher","unstructured":"Chen J, Lin S, Liu C (2014) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 11. https:\/\/doi.org\/10.1002\/14651858.CD004800.pub3","key":"5136_CR7","DOI":"10.1002\/14651858.CD004800.pub3"},{"doi-asserted-by":"publisher","unstructured":"Wang Y, Parker CE, Feagan BG, MacDonald JK (2016) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev:CD000544. https:\/\/doi.org\/10.1002\/14651858.CD000544.pub4","key":"5136_CR8","DOI":"10.1002\/14651858.CD000544.pub4"},{"key":"5136_CR9","doi-asserted-by":"publisher","first-page":"CD000543","DOI":"10.1002\/14651858.CD000543.pub4","volume":"4","author":"Y Wang","year":"2016","unstructured":"Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK, Cochrane IBD Group (2016) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4:CD000543. https:\/\/doi.org\/10.1002\/14651858.CD000543.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"5136_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, Tilg H, van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P, on behalf of ECCO (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11:3\u201325. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw168","journal-title":"J Crohns Colitis"},{"key":"5136_CR11","doi-asserted-by":"publisher","first-page":"CD008870","DOI":"10.1002\/14651858.CD008870.pub2","volume":"7","author":"W-C Lim","year":"2016","unstructured":"Lim W-C, Wang Y, MacDonald JK, Hanauer S (2016) Aminosalicylates for induction of remission or response in Crohn\u2019s disease. Cochrane Database Syst Rev 7:CD008870. https:\/\/doi.org\/10.1002\/14651858.CD008870.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"5136_CR12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3899\/jrheum.161518","volume":"44","author":"F Cantini","year":"2017","unstructured":"Cantini F, Niccoli L, Nannini C, Cassar\u00e0 E, Kaloudi O, Rizzello F, Gionchetti P (2017) Case-control study on dactylitis, enthesitis, and anterior uveitis in spondyloarthritis associated with inflammatory bowel diseases: role of coexistent psoriasis. J Rheumatol 44:1341\u20131346. https:\/\/doi.org\/10.3899\/jrheum.161518","journal-title":"J Rheumatol"},{"key":"5136_CR13","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00417-018-4082-x","volume":"256","author":"MM Zu Hoerste","year":"2018","unstructured":"Zu Hoerste MM, Walscheid K, Tappeiner C et al (2018) The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol 256:1985\u20131992. https:\/\/doi.org\/10.1007\/s00417-018-4082-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"Pt 3A","key":"5136_CR14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/eye.2000.84","volume":"14","author":"JM Benitez-Del-Castillo","year":"2000","unstructured":"Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Ba\u00f1ares A (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye Lond Engl 14(Pt 3A):340\u2013343. https:\/\/doi.org\/10.1038\/eye.2000.84","journal-title":"Eye Lond Engl"},{"key":"5136_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199502023320503","volume":"332","author":"BG Feagan","year":"1995","unstructured":"Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, Hanauer SB, McDonald JWD (1995) Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators. N Engl J Med 332:292\u2013297. https:\/\/doi.org\/10.1056\/NEJM199502023320503","journal-title":"N Engl J Med"},{"doi-asserted-by":"publisher","unstructured":"McDonald JWD, Wang Y, Tsoulis DJ et al (2014) Methotrexate for induction of remission in refractory Crohn\u2019s disease. Cochrane Database Syst Rev:CD003459. https:\/\/doi.org\/10.1002\/14651858.CD003459.pub4","key":"5136_CR16","DOI":"10.1002\/14651858.CD003459.pub4"},{"key":"5136_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1053\/j.gastro.2015.10.050","volume":"150","author":"F Carbonnel","year":"2016","unstructured":"Carbonnel F, Colombel JF, Filippi J et al (2016) Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology 150:380\u2013388.e4. https:\/\/doi.org\/10.1053\/j.gastro.2015.10.050","journal-title":"Gastroenterology"},{"doi-asserted-by":"publisher","unstructured":"Wang Y, MacDonald JK, Vandermeer B et al (2015) Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev:CD007560. https:\/\/doi.org\/10.1002\/14651858.CD007560.pub3","key":"5136_CR18","DOI":"10.1002\/14651858.CD007560.pub3"},{"key":"5136_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/1744666X.2018.1513329","volume":"14","author":"C Felice","year":"2018","unstructured":"Felice C, Pugliese D, Papparella LG, Pizzolante F, Onori E, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A (2018) Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert Rev Clin Immunol 14:751\u2013759. https:\/\/doi.org\/10.1080\/1744666X.2018.1513329","journal-title":"Expert Rev Clin Immunol"},{"key":"5136_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/ard.2006.054098","volume":"66","author":"H Haibel","year":"2007","unstructured":"Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, Sieper J (2007) No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66:419\u2013421. https:\/\/doi.org\/10.1136\/ard.2006.054098","journal-title":"Ann Rheum Dis"},{"key":"5136_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","volume":"86","author":"H Malchow","year":"1984","unstructured":"Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H (1984) European Cooperative Crohn\u2019s Disease Study (ECCDS): results of drug treatment. Gastroenterology 86:249\u2013266","journal-title":"Gastroenterology"},{"key":"5136_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","volume":"77","author":"RW Summers","year":"1979","unstructured":"Summers RW, Switz DM, Sessions JT et al (1979) National Cooperative Crohn\u2019s Disease Study: results of drug treatment. Gastroenterology 77:847\u2013869","journal-title":"Gastroenterology"},{"doi-asserted-by":"publisher","unstructured":"Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO, Cochrane IBD Group (2003) Corticosteroids for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev:CD000301. https:\/\/doi.org\/10.1002\/14651858.CD000301","key":"5136_CR23","DOI":"10.1002\/14651858.CD000301"},{"key":"5136_CR24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, G\u00e9her P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Comp\u00e0n V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978\u2013991. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"key":"5136_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/annrheumdis-2012-203055","volume":"73","author":"H Haibel","year":"2014","unstructured":"Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J (2014) Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 73:243\u2013246. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203055","journal-title":"Ann Rheum Dis"},{"key":"5136_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000545.pub5","volume":"10","author":"N Chande","year":"2016","unstructured":"Chande N, Townsend CM, Parker CE, MacDonald JK (2016) Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 10:CD000545. https:\/\/doi.org\/10.1002\/14651858.CD000545.pub5","journal-title":"Cochrane Database Syst Rev"},{"doi-asserted-by":"publisher","unstructured":"Timmer A, Patton PH, Chande N et al (2016) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev:CD000478. https:\/\/doi.org\/10.1002\/14651858.CD000478.pub4","key":"5136_CR27","DOI":"10.1002\/14651858.CD000478.pub4"},{"doi-asserted-by":"publisher","unstructured":"Chande N, Patton PH, Tsoulis DJ et al (2015) Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev:CD000067. https:\/\/doi.org\/10.1002\/14651858.CD000067.pub3","key":"5136_CR28","DOI":"10.1002\/14651858.CD000067.pub3"},{"key":"5136_CR29","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/14712598.2017.1347156","volume":"17","author":"X Guillot","year":"2017","unstructured":"Guillot X, Prati C, Sondag M, Wendling D (2017) Etanercept for treating axial spondyloarthritis. Expert Opin Biol Ther 17:1173\u20131181. https:\/\/doi.org\/10.1080\/14712598.2017.1347156","journal-title":"Expert Opin Biol Ther"},{"key":"5136_CR30","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3899\/jrheum.160952","volume":"44","author":"A Bieber","year":"2017","unstructured":"Bieber A, Fawaz A, Novofastovski I, Mader R (2017) Antitumor necrosis factor-\u03b1 therapy associated with inflammatory bowel disease: three cases and a systematic literature review. J Rheumatol 44:1088\u20131095. https:\/\/doi.org\/10.3899\/jrheum.160952","journal-title":"J Rheumatol"},{"key":"5136_CR31","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet Lond Engl 359:1541\u20131549. https:\/\/doi.org\/10.1016\/S0140-6736(02)08512-4","journal-title":"Lancet Lond Engl"},{"key":"5136_CR32","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJS, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462\u20132476. https:\/\/doi.org\/10.1056\/NEJMoa050516","journal-title":"N Engl J Med"},{"key":"5136_CR33","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","volume":"128","author":"G J\u00e4rnerot","year":"2005","unstructured":"J\u00e4rnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karl\u00e9n P, Gr\u00e4nn\u00f6 C, Vilien M, Str\u00f6m M, Danielsson \u00c5, Verbaan H, Hellstr\u00f6m PM, Magnuson A, Curman B (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805\u20131811. https:\/\/doi.org\/10.1053\/j.gastro.2005.03.003","journal-title":"Gastroenterology"},{"key":"5136_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, Burisch J, de Vos M, de Vries AM, Dick AD, Juillerat P, Karlsen TH, Koutroubakis I, Lakatos PL, Orchard T, Papay P, Raine T, Reinshagen M, Thaci D, Tilg H, Carbonnel F, for the European Crohn\u2019s and Colitis Organisation [ECCO] (2016) The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10:239\u2013254. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv213","journal-title":"J Crohns Colitis"},{"key":"5136_CR35","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P, UNITI\u2013IM-UNITI Study Group (2016) Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 375:1946\u20131960. https:\/\/doi.org\/10.1056\/NEJMoa1602773","journal-title":"N Engl J Med"},{"key":"5136_CR36","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381:1201\u20131214. https:\/\/doi.org\/10.1056\/NEJMoa1900750","journal-title":"N Engl J Med"},{"key":"5136_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJMc1915042","volume":"382","author":"CR Rowan","year":"2020","unstructured":"Rowan CR, Boland K, Harewood GC (2020) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 382:91. https:\/\/doi.org\/10.1056\/NEJMc1915042","journal-title":"N Engl J Med"},{"key":"5136_CR38","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet Lond Engl 382:780\u2013789. https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2","journal-title":"Lancet Lond Engl"},{"key":"5136_CR39","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Hermann K-GA, Callhoff J, Listing J, Sieper J (2014) Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73:817\u2013823. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204248","journal-title":"Ann Rheum Dis"},{"key":"5136_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, Harrison DD, Hsia EC, Heijde D, Ariel F, Asnal CA, Berman A, Citera G, Rodriguez G, Savio VG, Bird P, Griffiths H, Nicholls D, Rischmueller M, Zochling J, de Vlam K, Malaise M, Toukap AN, van den Bosch F, Vanhoof J, Bonfiglioli R, Keiserman M, Scotton AS, Xavier R, Ximenes AC, Atanasov A, Goranov I, Kazmin I, Licheva RN, Nikolov N, Oparanov B, Stoilov R, Bessette L, Rodrigues J, Bortilik L, Dokoupilova E, Dvoarak Z, Galatikova D, Nemec P, Podrazilova L, Simkova G, Stejfova Z, Moravcova R, Vitek P, Cantagrel A, Baillet A, Banneville B, Combe B, Breban M, Nguyen M, Goupille P, Braun J, Everding A, Kekow J, Koenig R, Rubbert-Roth A, Witte T, Bartha A, Drescher E, Kerekes K, Kovacs A, Pulai J, Rojkovich B, Szanto S, Toth E, Avila H, Torre IG, Irazoque F, Maradiaga M, Pacheco C, Brzosko M, Dudek A, Jeka S, Krogulec M, Kwiatkowska B, Wiland P, Wojciechowski R, Zielinska A, Santos H, Bugrova O, Christyakov V, Gorbunov V, Ilivanova E, Zemerova E, Kamalova R, Kameneva T, Macievskaya G, Marusenko I, Maslyansky A, Myasoedova S, Myasoutova L, Nemtsov B, Nesmeyanova O, Plaksina T, Pokrovskaya T, Polyakova S, Rebrov A, Savina L, Smakotina S, Stanislav M, Ukhanova O, Vinogradova I, Zonova E, Baek HJ, Kim TH, Lee CK, Lee SH, Lee SH, Lee SS, Park SH, Song YW, Suh CH, Ramos JA, Blanco FJ, Collantes E, Diaz MC, Vivar MLG, Gratacos J, Juanola X, Chen DY, Chen HC, Chen KH, Chen YC, Chiu YM, Luo SF, Tsai ST, Tseng JC, Wei CC, Weng MY, Abrahamovych O, Reshotko D, Golovchenko O, Hospodarsky I, Iaremenko O, Levchenko O, Dudnyk O, Garmish O, Grishyna O, Protsenko G, Rekalov D, Smiyan S, Stanislavchuk M, Trypilka S, Tseluyko V, Turianytsia S, Vasylets V, Virstyuk N, Kleban Y, Ciurtin C, Gaffney K, Gunasekera W, Mackay K, Packham J, Sengupta R, Tahir H, Aelion J, Bennett R, Deodhar A, Gonzalez-Paoli J, Griffin RM, Grisanti M, Mallepalli J, Peters E, Schechtman J, Singhal A (2019) Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in Axial spondyloarthritis. Arthritis Rheumatol Hoboken NJ 71:258\u2013270. https:\/\/doi.org\/10.1002\/art.40728","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"5136_CR41","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Pan\u00e9s J (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376:1723\u20131736. https:\/\/doi.org\/10.1056\/NEJMoa1606910","journal-title":"N Engl J Med"},{"key":"5136_CR42","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, Li D, Menon S, Kanik KS (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76:1340\u20131347. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210322","journal-title":"Ann Rheum Dis"},{"key":"5136_CR43","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","volume":"12","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Ghosh S, Panes J et al (2014) A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol 12:1485\u20131493.e2. https:\/\/doi.org\/10.1016\/j.cgh.2014.01.029","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5136_CR44","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","volume":"66","author":"J Pan\u00e9s","year":"2017","unstructured":"Pan\u00e9s J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E (2017) Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials. Gut 66:1049\u20131059. https:\/\/doi.org\/10.1136\/gutjnl-2016-312735","journal-title":"Gut"},{"key":"5136_CR45","doi-asserted-by":"publisher","first-page":"101606","DOI":"10.1016\/j.bpg.2019.03.002","volume":"38\u201339","author":"C Ma","year":"2019","unstructured":"Ma C, Jairath V, Vande Casteele N (2019) Pharmacology, efficacy and safety of JAK inhibitors in Crohn\u2019s disease. Best Pract Res Clin Gastroenterol 38\u201339:101606. https:\/\/doi.org\/10.1016\/j.bpg.2019.03.002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"5136_CR46","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair HA (2019) Secukinumab: a review in ankylosing spondylitis. Drugs 79:433\u2013443. https:\/\/doi.org\/10.1007\/s40265-019-01075-3","journal-title":"Drugs"},{"key":"5136_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, \u00d8stergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J, Morin F, Rahman P, Ariel F, Berman A, Carrio J, Lucero E, Cocco JM, Hidalgo RP, Velasco J, Viola DO, Grisar J, Resch H, Scheinecker C, Melazzi AC, Roimicher L, Scotton AS, Rodriguez AAB, Molina FFC, Barragan SD, Skinner CM, Tena CFP, Remus CRR, Rodriguez JCR, Hong SJ, Kang SW, Lee CK, Lee EB, Lee SH, Park MC, Lee SH, Dokoupilova E, Dvorak Z, Malcova M, Pvelka K, Eklund KK, Jarvinen P, Karjalainen A, Paimela L, Taniguchi Y, Tsuda T, Tada K, Dobashi H, Inui K, Ueki Y, Matsumoto Y, Hatta K, Atsumi T, Goto H, Honjo S, Matsui K, Takakubo Y, Neeck G, Wagner S, Braun J, Blicharshi T, Dudek A, Hrycai P, Plebanski R, Drabiszcak-Piatkowska J, Brzezicki J, Krogulec M, Opris-Belinski D, Ramazan AM, Tronaru L, van de Sande MG, Matsievskaya G, Schmidt E, Stanislav M, Yakushin S, Ershova O, Rebroy A, Churchill MA, Flint KP, Greenwald M, Howell MP, Kaine JL, Kivitz A, Klein SJ, Mueller EC, Peters EA, Querubin R, Sayers ME, Scoville CD, Shanahan JC, Roseff R, Hull JE, Mallepalli JR, Sebai MB, Kimmel SC, Goddard DH, Mease PJ, Harris MD, Mabaquiao AR, Diegel RJ, Thai C, Rivera TL, Perez-de Jesus A, Soto-Raices O, Toro-Torres R, Pantojas C (2020) Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet Lond Engl 395:53\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(19)32971-X","journal-title":"Lancet Lond Engl"},{"key":"5136_CR48","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, J\u00e4rvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD, the COAST\u2010W Study Group, Antolini C, Azevedo V, Barkham M, Rodriguez AAB, Berman A, Blicharski T, Brzezicki J, Burmester G, Carrio J, Collantes E, Combe B, Cons-Molina F, Cortes-Maisonet G, Dudek A, Barragan SD, Elkayam O, Flint K, Galeazzi M, Gaylis N, Goddard D, Fernandez CG, Goupille P, Masmitja JG, Greenwald M, Gremese E, Hong SJ, Howell M, Hrycaj P, Ince A, Ju JH, Kaine J, Kang SW, Keiserman M, Kim TH, Kivitz A, Klein S, Kremer J, Lee SH, Lee CK, Lee SH, Lidman R, Loveless J, Lucero E, Cocco JM, Marcolino F, Mariette X, Mehta D, Morin F, Moscovici Y, Mueller E, Mysler E, Blasco FN, Nguyen M, Pantojas C, Park MC, Jesus APD, Peters E, Plebanski R, Querubin R, Remus CR, Reitblat T, Rivera T, Rodriguez JCR, Sayers M, Scotton A, Scoville C, Shaw D, Shin K, Singhal A, Skinner C, Soto-Raices O, Soubrier M, Szymanska M, Thai C, Sande M, Wells A, Wojciechowski R, Xavier R, Ximenes A, Zisman D (2019) Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol Hoboken NJ 71:599\u2013611. https:\/\/doi.org\/10.1002\/art.40753","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"5136_CR49","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SPL, for the Secukinumab in Crohn\u2019s Disease Study Group (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:1693\u20131700. https:\/\/doi.org\/10.1136\/gutjnl-2011-301668","journal-title":"Gut"},{"key":"5136_CR50","doi-asserted-by":"publisher","first-page":"2975631","DOI":"10.1155\/2019\/2975631","volume":"2019","author":"TG Achufusi","year":"2019","unstructured":"Achufusi TG, Harnee PS, Rawlins S (2019) A rare case of new-onset ulcerative colitis following initiation of secukinumab. Case Rep Med 2019:2975631\u20132975635. https:\/\/doi.org\/10.1155\/2019\/2975631","journal-title":"Case Rep Med"},{"key":"5136_CR51","doi-asserted-by":"publisher","first-page":"720","DOI":"10.17235\/reed.2019.5841\/2018","volume":"111","author":"R Rodr\u00edguez Moncada","year":"2019","unstructured":"Rodr\u00edguez Moncada R, V\u00e1zquez Mor\u00f3n JM, Pallar\u00e9s Manrique H (2019) The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease? Rev Espanola Enfermedades Dig 111:720\u2013721. https:\/\/doi.org\/10.17235\/reed.2019.5841\/2018","journal-title":"Rev Espanola Enfermedades Dig"},{"key":"5136_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Leonardi C, Langley RG et al (2017) Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol 76:441\u2013448.e2. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.027","journal-title":"J Am Acad Dermatol"},{"key":"5136_CR53","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.dld.2015.12.016","volume":"48","author":"A Armuzzi","year":"2016","unstructured":"Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F, Ardizzone S, Armuzzi A, Castiglione F, Danese S, Daperno M, Fantini M, Fiorino G, Frieri G, Gionchetti P, Neri L, Orlando A, Rizzello F, Lia Scribano M, Carlo Sturniolo G, Vecchi M (2016) Expert consensus paper on the use of vedolizumab for the management of patients with moderate-to-severe inflammatory bowel disease. Dig Liver Dis 48:360\u2013370. https:\/\/doi.org\/10.1016\/j.dld.2015.12.016","journal-title":"Dig Liver Dis"},{"key":"5136_CR54","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","volume":"76","author":"G Varkas","year":"2017","unstructured":"Varkas G, Thevissen K, De Brabanter G et al (2017) An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis 76:878\u2013881. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210233","journal-title":"Ann Rheum Dis"},{"key":"5136_CR55","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10067-018-4357-y","volume":"38","author":"S Tamanini","year":"2019","unstructured":"Tamanini S, Fredi M, Crisafulli F, Lazzaroni MG, Tincani A, Franceschini F (2019) Letter to editor: new onset\/recurrence of inflammatory arthralgia\/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease. Clin Rheumatol 38:609\u2013610. https:\/\/doi.org\/10.1007\/s10067-018-4357-y","journal-title":"Clin Rheumatol"},{"key":"5136_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-211011","volume":"76","author":"A Orlando","year":"2017","unstructured":"Orlando A, Orlando R, Ciccia F, Renna S, Rizzo A, Cottone M, Macaluso FS (2017) Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. Ann Rheum Dis 76:e31. https:\/\/doi.org\/10.1136\/annrheumdis-2016-211011","journal-title":"Ann Rheum Dis"},{"key":"5136_CR57","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.rhum.2017.11.009","volume":"85","author":"D Wendling","year":"2018","unstructured":"Wendling D, Lukas C, Prati C, Claudepierre P, Gossec L, Goupille P, Hudry C, Miceli-Richard C, Molto A, Pham T, Saraux A, Dougados M (2018) Actualisation 2018 des recommandations de la Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite. Rev Rhum 85:222\u2013230. https:\/\/doi.org\/10.1016\/j.rhum.2017.11.009","journal-title":"Rev Rhum"},{"key":"5136_CR58","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L (2019) 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic Axial spondyloarthritis. Arthritis Care Res 71:1285\u20131299. https:\/\/doi.org\/10.1002\/acr.24025","journal-title":"Arthritis Care Res"},{"issue":"Suppl 1","key":"5136_CR59","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/ibd.3780070503","volume":"7","author":"PJ Rutgeerts","year":"2001","unstructured":"Rutgeerts PJ (2001) Conventional treatment of Crohn\u2019s disease: objectives and outcomes. Inflamm Bowel Dis 7(Suppl 1):S2\u2013S8. https:\/\/doi.org\/10.1002\/ibd.3780070503","journal-title":"Inflamm Bowel Dis"},{"key":"5136_CR60","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D\u02bcHaens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ord\u00e1s I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, van Assche G, Danese S, Panes J, Bouguen G, O\u02bcDonnell S, Pariente B, Winer S, Hanauer S, Colombel JF (2015) Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110:1324\u20131338. https:\/\/doi.org\/10.1038\/ajg.2015.233","journal-title":"Am J Gastroenterol"},{"key":"5136_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41575-019-0211-1","volume":"17","author":"S Danese","year":"2019","unstructured":"Danese S, Roda G, Peyrin-Biroulet L (2019) Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nat Rev Gastroenterol Hepatol 17:1\u20132. https:\/\/doi.org\/10.1038\/s41575-019-0211-1","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5136_CR62","doi-asserted-by":"publisher","first-page":"204062232090429","DOI":"10.1177\/2040622320904295","volume":"11","author":"P Coto","year":"2020","unstructured":"Coto P, Riestra S, Rozas P, Se\u00f1aris A, Queiro R (2020) Improving the standard of care for patients with spondyloarthritis-related immune inflammatory conditions: results of a Delphi study and proposal for early detection. Ther Adv Chronic Dis 11:2040622320904295. https:\/\/doi.org\/10.1177\/2040622320904295","journal-title":"Ther Adv Chronic Dis"},{"key":"5136_CR63","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/ecco-jcc\/jjx106","volume":"11","author":"JN Pe\u00f1a-S\u00e1nchez","year":"2017","unstructured":"Pe\u00f1a-S\u00e1nchez JN, Lix LM, Teare GF, Li W, Fowler SA, Jones JL (2017) Impact of an integrated model of care on outcomes of patients with inflammatory bowel diseases: evidence from a population-based study. J Crohns Colitis 11:1471\u20131479. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx106","journal-title":"J Crohns Colitis"},{"key":"5136_CR64","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Harbord","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Moln\u00e1r T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, for the European Crohn\u2019s and Colitis Organisation [ECCO] (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 11:769\u2013784. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx009","journal-title":"J Crohns Colitis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05136-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05136-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05136-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T23:52:57Z","timestamp":1621295577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05136-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5136"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05136-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,5,18]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}